866-997-4948(US-Canada Toll Free)

Peritoneal Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 346 Pages

Peritoneal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Peritoneal Cancer - Pipeline Review, H2 2014, provides an overview of the Peritoneal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peritoneal Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Peritoneal Cancer - Overview 10
Pipeline Products for Peritoneal Cancer - Comparative Analysis 11
Peritoneal Cancer - Therapeutics under Development by Companies 12
Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Peritoneal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Peritoneal Cancer - Products under Development by Companies 21
Peritoneal Cancer - Products under Investigation by Universities/Institutes 24
Peritoneal Cancer - Companies Involved in Therapeutics Development 25
Johnson & Johnson 25
Boehringer Ingelheim GmbH 26
F. Hoffmann-La Roche Ltd. 27
Amgen Inc. 28
AstraZeneca PLC 29
GlaxoSmithKline plc 30
Bioniche Life Sciences, Inc. 31
MedImmune, LLC 32
Daiichi Sankyo Company, Limited 33
Oxford BioMedica plc 34
Millennium Pharmaceuticals, Inc. 35
Novartis AG 36
Astellas Pharma Inc. 37
ImmunoGen, Inc. 38
Astex Pharmaceuticals, Inc. 39
Bayer AG 40
Incyte Corporation 41
Hemispherx Biopharma, Inc. 42
Celldex Therapeutics, Inc. 43
Active Biotech AB 44
Bionomics Limited 45
Oncolytics Biotech Inc. 46
OXiGENE, Inc. 47
Topotarget A/S 48
NeoStem, Inc. 49
Pharmacyclics, Inc. 50
Synta Pharmaceuticals Corp. 51
Oasmia Pharmaceutical AB 52
MabVax Therapeutics, Inc. 53
Acceleron Pharma, Inc. 54
TRION Pharma GmbH 55
Cerulean Pharma, Inc. 56
OncoMed Pharmaceuticals, Inc. 57
TetraLogic Pharmaceuticals 58
Merrimack Pharmaceuticals, Inc. 59
Innate Therapeutics Limited 60
CritiTech, Inc. 61
Immunotope, Inc. 62
Immunovaccine, Inc. 63
Pharma Mar, S.A. 64
VentiRx Pharmaceuticals, Inc. 65
Genelux Corporation 66
TRACON Pharmaceuticals, Inc. 67
Lee's Pharmaceutical Holdings Limited 68
Clovis Oncology, Inc. 69
EGEN, Inc. 70
Advanced Accelerator Applications 71
Sanofi Pasteur SA 72
Peritoneal Cancer - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Combination Products 74
Assessment by Target 75
Assessment by Mechanism of Action 79
Assessment by Route of Administration 83
Assessment by Molecule Type 86
Drug Profiles 89
pazopanib hydrochloride - Drug Profile 89
trebananib - Drug Profile 93
paclitaxel - Drug Profile 96
binimetinib - Drug Profile 98
nintedanib - Drug Profile 102
bevacizumab - Drug Profile 105
trabectedin - Drug Profile 109
rucaparib phosphate - Drug Profile 112
sorafenib tosylate - Drug Profile 115
alisertib - Drug Profile 119
selumetinib sulfate - Drug Profile 123
SGI-110 - Drug Profile 126
abiraterone acetate - Drug Profile 129
tasquinimod - Drug Profile 132
dalantercept - Drug Profile 134
elesclomol - Drug Profile 136
belinostat - Drug Profile 138
TroVax - Drug Profile 141
SG-2000 - Drug Profile 144
pelareorep - Drug Profile 146
nintedanib - Drug Profile 150
catumaxomab - Drug Profile 153
CRLX-101 - Drug Profile 155
VTX-2337 - Drug Profile 157
gimatecan - Drug Profile 159
seribantumab - Drug Profile 161
exatecan mesylate - Drug Profile 164
TRC-105 - Drug Profile 166
EGEN-001 - Drug Profile 168
NSC-748933 - Drug Profile 170
INCB-24360 - Drug Profile 171
birinapant - Drug Profile 173
Cancer Stem Cell Therapy - Drug Profile 175
DPX-Survivac - Drug Profile 176
linsitinib - Drug Profile 179
CDX-1401 - Drug Profile 182
ganetespib - Drug Profile 184
demcizumab - Drug Profile 188
erismodegib - Drug Profile 191
GLONC-1 - Drug Profile 193
fosbretabulin tromethamine - Drug Profile 195
BNC-105P - Drug Profile 199
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 201
birinapant + conatumumab - Drug Profile 203
abexinostat hydrochloride - Drug Profile 205
8H9-MAb - Drug Profile 207
IMT-1012 - Drug Profile 208
vCP-2292 - Drug Profile 209
paclitaxel - Drug Profile 210
OC-DC Vaccine - Drug Profile 212
MV-NIS Vaccine - Drug Profile 213
IMGN-853 - Drug Profile 215
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 216
MesoCART - Drug Profile 217
rintatolimod - Drug Profile 218
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 220
MIS-416 - Drug Profile 221
Theranean - Drug Profile 223
Peritoneal Cancer - Recent Pipeline Updates 224
Peritoneal Cancer - Dormant Projects 336
Peritoneal Cancer - Discontinued Products 337
Peritoneal Cancer - Product Development Milestones 338
Featured News & Press Releases 338
Appendix 341
Methodology 341
Coverage 341
Secondary Research 341
Primary Research 341
Expert Panel Validation 341
Contact Us 342
Disclaimer 342

List of Tables
Number of Products under Development for Peritoneal Cancer, H2 2014 14
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Development by Companies, H2 2014 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Products under Development by Companies, H2 2014 25
Products under Development by Companies, H2 2014 (Contd..1) 26
Products under Development by Companies, H2 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2014 29
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 30
Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 31
Peritoneal Cancer - Pipeline by Amgen Inc., H2 2014 32
Peritoneal Cancer - Pipeline by AstraZeneca PLC, H2 2014 33
Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 34
Peritoneal Cancer - Pipeline by Bioniche Life Sciences, Inc., H2 2014 35
Peritoneal Cancer - Pipeline by MedImmune, LLC, H2 2014 36
Peritoneal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 37
Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H2 2014 38
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 39
Peritoneal Cancer - Pipeline by Novartis AG, H2 2014 40
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H2 2014 42
Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 43
Peritoneal Cancer - Pipeline by Bayer AG, H2 2014 44
Peritoneal Cancer - Pipeline by Incyte Corporation, H2 2014 45
Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2014 46
Peritoneal Cancer - Pipeline by Active Biotech AB, H2 2014 48
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 50
Peritoneal Cancer - Pipeline by Topotarget A/S, H2 2014 52
Peritoneal Cancer - Pipeline by NeoStem, Inc., H2 2014 53
Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 54
Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 55
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 56
Peritoneal Cancer - Pipeline by MabVax Therapeutics, Inc., H2 2014 57
Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 58
Peritoneal Cancer - Pipeline by TRION Pharma GmbH, H2 2014 59
Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 60
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 62
Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 63
Peritoneal Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 64
Peritoneal Cancer - Pipeline by CritiTech, Inc., H2 2014 65
Peritoneal Cancer - Pipeline by Immunotope, Inc., H2 2014 66
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H2 2014 68
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 69
Peritoneal Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 71
Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 72
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 73
Peritoneal Cancer - Pipeline by EGEN, Inc., H2 2014 74
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications, H2 2014 75
Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2014 76
Assessment by Monotherapy Products, H2 2014 77
Assessment by Combination Products, H2 2014 78
Number of Products by Stage and Target, H2 2014 81
Number of Products by Stage and Mechanism of Action, H2 2014 85
Number of Products by Stage and Route of Administration, H2 2014 89
Number of Products by Stage and Molecule Type, H2 2014 92
Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 228
Peritoneal Cancer - Dormant Projects, H2 2014 340
Peritoneal Cancer - Discontinued Products, H2 2014 341

List of Figures
Number of Products under Development for Peritoneal Cancer, H2 2014 14
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Products, H2 2014 24
Assessment by Monotherapy Products, H2 2014 77
Number of Products by Top 10 Target, H2 2014 79
Number of Products by Stage and Top 10 Target, H2 2014 80
Number of Products by Top 10 Mechanism of Action, H2 2014 83
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 84
Number of Products by Top 10 Route of Administration, H2 2014 87
Number of Products by Stage and Top 10 Route of Administration, H2 2014 88
Number of Products by Top 10 Molecule Type, H2 2014 90
Number of Products by Stage and Top 10 Molecule Type, H2 2014 91

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *